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Complete sequence-based pathway 
analysis by differential on-chip DNA 
and RNA extraction from a single 
cell
D. van Strijp1, R. C. M. Vulders1, N. A. Larsen2, J. Schira3, L. Baerlocher3, M. A. van Driel1, M. 
Pødenphant4, T. S. Hansen2, A. Kristensen4, K. U. Mir5, T. Olesen2, W. F. J. Verhaegh1, R. Marie 
 4 & P. J. van der Zaag  1
We demonstrate on-chip, differential DNA and RNA extraction from a single cell using a microfluidic 
chip and a two-stage lysis protocol. This method enables direct use of the whole extract, without 
additional washing steps, reducing sample loss. Using this method, the tumor driving pathway in 
individual cells from a colorectal cancer cell line was determined by applying a Bayesian computational 
pathway model to sequences obtained from the RNA fraction of a single cell and, the mutations driving 
the pathway were determined by analyzing sequences obtained from the DNA fraction of the same 
single cell. This combined functional and mutational pathway assessment of a single cell could be of 
significant value for dissecting cellular heterogeneity in tumors and analyzing single circulating tumor 
cells.
Accumulation of genetic changes leads to inter-cellular heterogeneity within tumours producing sub-populations 
of cells that have different potentials for metastasis and drug resistance1. Molecular differences between cells can 
be investigated by transcriptome2, 3 and genome4, 5 sequencing. We have developed a novel microfluidic device and 
a two-stage cell lysis method to extract and sequence separately both RNA and DNA from the same single cell. We 
applied this to cells from colorectal cancer cell lines to show, using a Bayesian computational pathway model6, that 
Wnt transcriptional pathway activity could be derived from the obtained single cell RNA profile. Whole-genome 
sequence data from the same cell revealed which genes in the Wnt pathway were mutated and hence candidate 
drivers of the aberrant signalling. Such single-cell resolved molecular phenotype to genotype correlations have 
implications in cancer management, including prognosis, prediction and personalized treatment.
Sequencing tumours in routine clinical practice reveals a multitude of variants, whose relevance for the indi-
vidual patient is difficult to assess. This has led to discussions about driver and passenger mutations1 and with 
the premise that cancer is a clonal evolutionary process of somatic mutations7, the current focus is on known 
actionable mutations8. Unfortunately, a direct relationship does not always exist between DNA mutations and the 
activated molecular pathways driving tumor growth. In medulloblastoma, a direct relationship exists between 
mutations in CTNNB1 (coding for ß-catenin) and Wnt activity. In liver carcinoma such a clear relationship 
between CTNNB1 mutations and the Wnt pathway activation does not exist6, while in breast cancer, a mutation 
in PIK3CA is not always predictive of PI3K inhibitor response9. Epigenetic changes may also activate molecular 
pathways. We propose to identify driver mutations by determining both the genotype and the molecular phe-
notype10 of a tumor6, 11, 12: mRNA patterns will reveal which pathway is activated and DNA mutations will reveal 
where within the pathway the deregulation occurs. Thus, druggable mutations that might be the root cause of the 
activated pathway can be found. An ability to conduct such genotype and molecular phenotype analysis on single 
cells provides the resolution needed to address heterogeneity within a tumour and the sensitivity for a similar 
analysis on circulating tumour cells (CTCs).
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Two recent approaches describe analysing the genome and transcriptome from the same single cell: DR-seq 
(gDNA-mRNA sequencing)13 and G&T-seq (genome and transcriptome sequencing)14. Both are bench protocols 
with multiple handling steps, not ideal in a diagnostic setting and risking sample loss. We report a two-step lysis 
procedure on cells captured in picoliter traps in a microfluidic chip, to extract consecutively the RNA and DNA 
from a single cell. This simplifies processing of the extracts and enables the use of conventional, commercial 
kits for single cell RNA and DNA amplification on the separated nucleic acid fractions. After sequencing both 
extracts, we assess complete pathway activity at both geno- and phenotypical level in single cells using a Bayesian 
network-based computational pathway model previously applied only to bulk samples6, 12.
Results
To sequence both RNA and DNA from the same single cell, we use a microfluidic chip to process cells and their 
content, plus a two-stage lysis procedure where the plasma membrane is lysed first to release the cytoplasmic 
RNA and then the nuclear membrane is lysed to release the DNA. A microfluidic chip is mounted in a set-up 
capable of affecting cell flow and monitoring individual cells and their processing (Fig. 1). Figure 1a gives a 
schematic diagram of the system, while Fig. 1b shows pictures. The system provides bright field and fluorescence 
in-situ monitoring of the cells and allows them to be processed in the chip by stepwise flow of reagents. The 
movement of the cells and reagent liquids in the chip is controlled by a pressure-driven system. A heating and 
cooling stage enables thermal cycling of the chip for nucleic acid amplification. Figure 1c shows the layout and a 
picture of the chips used. The pressure-driven microfluidics enables a valveless, passive, inexpensive, disposable 
chip to perform all necessary functions. Figure 1d shows how PBS buffer applied from the other inlet channels I1 
Figure 1. Single cell microfluidics instrument and chip. (a) Diagram and (b) picture of the set-up for operating 
the single cell platform. The system is a modified Philips BioCell FluidScope and provides bright field (BF) 
and epifluorescence (FL) in-situ monitoring of cells and their processing, a stage to mount microfluidic chips, 
focus automation and pressure-driven flow control (for details see Methods). A separate heating and cooling 
module in the set-up (see lower half Fig. 1b) enables nucleic acid amplification within the chip. The lower half of 
(b) shows also the position in which the microfluidic chip is mounted and the gasket through which pressure-
driven flow is applied. (c) Diagram and picture of the single-use injection-molded microfluidic chip. In the 
diagram S labels the sample input, I1 and I2 the two buffer inputs, Oi the in total 8 outputs and W the waste 
chamber. The insert shows a blow-up of the channel and two of the 8 traps. (d) Schematic diagram of how cells 
are aligned in the main channel by flow-pinching and delivered to the traps downstream.
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and I2 pushes the cells, flowing from inlet S to the waste chamber, in the direction of the traps, each connected to 
individual outlets (Oi with i being 1 to 8).
Figure 2a shows various steps in the two-stage lysis protocol for separate RNA and DNA extraction using 
the microfluidic chip. First calcein-stained cells are captured in pl volume traps. Calcein fluorescence allows 
Figure 2. Two-stage lysis. (a) Diagram of the process flow: a single cell is trapped and its membrane is lysed 
releasing the mRNA that is collected. Next, the DNA is stained with fluorescent YOYO-1 dye to confirm its 
presence in the trap before it is lysed and genomic DNA can be collected in the outlet. (b) Bright field and 
fluorescence and merged time-lapse images from the instrument, during trapping, cell membrane lysis (loss of 
cytosol dye) and staining of the nuclear DNA retained in the cell trap. The scale bar corresponds to 15 μm. The 
white arrow in bright-field image shows the position of the trapped cell. In the merged image the fluorescence is 
shown in colour.
www.nature.com/scientificreports/
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monitoring the presence and movement of these viable cells. Next the first lysis buffer (0.5x TBE containing 
0.5% (v/v) Triton X-100 to which the DNA intercalating YOYO-1 dye is added) is applied. This buffer lyses the 
cell membrane, releasing the cytosol contents into the trap outlets filled with 10–20 μl nuclease-free H2O, leav-
ing the nucleus with the DNA in the trap. This process can be monitored as a time-lapse series (Fig. 2b), where 
the top row shows the bright-field, the middle row the fluorescent, and the bottom row the merged images. 
Through pseudo-colors, the calcein (green) and YOYO-1 (blue) fluorescence have been highlighted. The first 
column shows the situation with a trapped cell (see arrow). After application of the first lysis buffer, the fluores-
cence due to the calcein disappears (second column). After ≃3 minutes the fluorescence signal reappears as the 
YOYO-1 dye stains the DNA (third column). The cytosol content of each separate cell is lysed into and collected 
from a separate outlet and processed off-chip to synthesize and amplify cDNA. Subsequently, the nuclear lysis is 
performed with a second buffer (0.5x TBE containing 0.5% (v/v) Triton X-100 and Protease K). This causes the 
disappearance of the DNA from the traps into the outlets; see fourth column Fig. 2b. After reagent addition for 
whole genome amplification (WGA), the system is put at 30 °C for on-chip WGA. The final step is a 60 °C heat kill 
to end the amplification process. Subsequently, each sample is collected and sent with the corresponding cDNA 
sample for sequencing.
Functional activity of the canonical Wnt pathway was analysed using a Bayesian network that represents its 
transcriptional program6, 12 with three types of nodes: (a) a transcription complex (TC), (b) Wnt target genes, and 
(c) expression level measurements of the target genes (Fig. 3a). The model quantitatively describes the relation 
between the TC and the target genes, and between each target gene and its associated measurements. Once such a 
model has been constructed from prior knowledge about which genes and expression levels to include, the model 
can be used on newly-analyzed samples by entering their measured expression values and applying Bayesian 
reasoning to infer the probability that the TC must have been active6, 15. The initial Bayesian Wnt pathway model, 
including 34 target genes, constructed using microarray data6, 16, is adapted to RNA-sequencing data here. The 
model was first calibrated on RNA-seq data from samples with known Wnt activity status based on analysis of 
microarray data (see GSE 24795) and literature17, using log2 RPKM measurements (reads per kilobase per million 
mapped reads): two Wnt active LS180 and SW1222 samples and two Wnt inactive RKO samples, shown as the 
first group in Fig. 3c.
Subsequently, the calibrated model was used on newly-analysed samples to infer the probability of TC activity. 
The model correctly classified CC20 and additional LS174T samples as Wnt inactive and Wnt active, respectively 
(labelled’verification’ in Fig. 3c), given previous microarray (see GSE24795) and literature data18. This verifica-
tion also showed that the amount of RNA input (1 or 10 ng), did not influence the results (first two’verification’ 
samples in Fig. 3c). No differences in reported pathway activity were found for the LS174T cell lines, whether 
purified RNA extracted from bulk samples, or cells themselves (e.g. crude lysate) were directly used as input. This 
is relevant because in the single cell experiments, cells will serve as input rather than purified RNA. Finally, there 
was no difference in predicted pathway activity between cell line samples from the Weatherall Institute (Oxford) 
or those purchased from the ATCC; even when 3–4 cells were used as input (data not shown). Finally, RNA-seq 
measurements of single cells were analysed (‘single cell’ group in Fig. 3c). All seven analysed single LS174T cells 
(green) were classified to be Wnt active, showing that the Bayesian model can determine Wnt activity in single 
cells. These single cells were not synchronized in order to assess the power of our approach for determining path-
way activity in a heterogeneous pool of cells. Figure 3d shows a cluster plot of the probability that the genes in 
the Bayesian Wnt model are up- or down-regulated compared to the threshold values set in the calibration step. 
Although RNA expression levels of individual genes varied between cells (see Fig. 3d), the model robustly infers 
Wnt pathway activity as it uses a panel of 34 target genes.
Some genes, up-regulated in LS174T verification samples with RNA as input (first four green bars), were not 
up-regulated when 1000 cells (with a similar RNA content) and single cells were used. These genes are generally 
expressed at low levels making them prone to disturbances in the amplification process, due to the presence of 
crude cell content. Still, from the calculated odds for the TC to be present in these samples (odds ratio ~1:1000), 
the Wnt pathway is active, despite some of these genes no longer being upregulated. The Bayesian Wnt model 
was constructed to give more weight to up-regulated genes in test samples, by a factor of approximately five, than 
non-up-regulated genes (see the probability Tables in Eq. (1)6) because of the intrinsic noise in biological systems. 
A number of confounding factors exist that may lower the expression of a gene even though the pathway and 
its transcription complex are active19. Bayesian modeling is very suited to deal with this noisiness. As a negative 
biological control we analysed single RKO cells (grey), known to be Wnt inactive based on microarray data (see 
GSE24795). As Fig. 3c shows, all 6 cells studied were inferred to be Wnt inactive. Our pathway model thus cor-
rectly classified all 7 Wnt active and 6 Wnt inactive validation samples (Fisher’s exact test p = 0.0006).
For the same cells, DNA isolated and amplified on chip was sequenced. Figure 4 shows the Lorenz (a) and 
coverage graphs (b) obtained for this data. The Lorenz graph in Fig. 4a displays the cumulative fraction of total 
reads as a function of the cumulative fraction of the genome covered. The advantage of a Lorenz graph is that 
it provides a good representation of the coverage diversity even at low coverage. In our initial experiments the 
percentage of non-covered bases was high and varying. After improving the temperature regulation, the percent-
age of non-covered bases could be reduced to 10.6 ± 0.9% for an average read depth of 16.2 ± 1.0, which is close 
to the 8.4% non-covered bases obtained for a bulk sample (see Supplementary Table S1), which is important 
for driver mutation identification. Moreover, this also compares favourably to previous single cell sequencing 
methods. For the multiple annealing and looping-based amplification cycles (MALBAC) method, coverages of 
85 up to 93% (≥1x) were achieved20. Other (bench-based) single cell RNA and DNA sequencing methods yield a 
coverage between 62–80% (at 0.6–2.5x) for DR-seq13 and 67.2 ± 8.1% for G&T-seq using multiple-displacement 
amplification (MDA)14. Note that in some publications these numbers are provided in comparison to the bulk 
coverage20. Therefore our results show the advantage of the on-chip DNA amplification for single cell DNA anal-
ysis to improve coverage. Figure 4b shows the coverage graph for these data i.e. the % of the genome covered vs 
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Figure 3. Complete Wnt pathway analysis results. (a) The structure of the Bayesian network used to model 
the transcriptional activity of a signal transductional pathway. (b) The panel shows putative driver mutations 
identified in the genes CTNNB1, KRAS, and PIK3CA for these samples, using the DNA derived from the same 
single cell for which the odds on Wnt activity are displayed in the corresponding columns below (c). (c) Results 
from Wnt pathway model analysis for the samples studied. Each sample result is represented by a bar with different 
colours for each cell line, as indicated. The y-axis shows the inferred odds of the Wnt pathway being active (on) 
versus inactive (off) on a logarithmic scale. For calibration, the RNA extracted from four colon cancer cell line 
experiments were used, which were known to be Wnt active (LS180, orange; SW1222 yellow) or inactive (RKO, 
grey) based on analysis of microarray data (see GSE 24795) and literature17. Subsequently the model was verified 
for LS174T (green) and a CC20 (black) samples known to be Wnt (in)active based on analysis of microarray data 
(see GSE 24795) and the literature18. Finally, the Wnt activity odds were inferred for the single cells processed: 
LS174T (green) and RKO (grey). All cells were correctly classified as Wnt active or inactive. (d) Cluster plot of the 
gene expression for the single cell data for LS174T and RKO cells including the expression data for bulk reference 
samples (LS180, SW122, RKO, LS174T and CC20) across the 34 genes constituting the Wnt profile, which are 
listed on the right hand-side6. The colour scale, as also shown on the left side, indicates the degree to which a gene’s 
expression is above (red) or below (blue) its threshold value set to separate the active from inactive calibration 
samples. See the main text for how the variation in the individual gene expressions translate into the resulting odds 
for the Wnt transcription complex activity i.e. Wnt pathway being (in)active.
www.nature.com/scientificreports/
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the coverage depth. This graph is useful as it shows the percentage of the bases that achieve the 20 or 30x coverage 
typically used for SNP calling. Note that further sequencing will shift the fraction of the bases with sufficient 
coverage, but it will not improve the fraction of the bases covered, as this is determined by the initial loss of DNA 
going into the first amplification step.
From a mutation analysis of the DNA sequencing data for samples with good coverage, C ≥ 70% of the 
genome, the known driver mutation in CTNNB1 (c.134 C > T) for the Wnt pathway in the LS174T cell line was 
found, see Fig. 3b. This CTNNB1 mutation leads to an amino acid change S45F, which alters potential GSK-3 β 
phosphorylation sites of β-catenin, thereby hampering its degradation and hence leading to activation of the 
TCF4/β-catenin transcription complex driving the canonical Wnt pathway21. Also other known mutations of 
LS174T cells in KRAS (c.35 G > A) and PIK3CA (c.3140 A > G) were found, see Fig. 3b. A mutation analysis of 
RKO single cells showed wild type CTNNB1 in 5 out of 5 cells (one had insufficient coverage), as expected for 
RKO and matching the Wnt pathway inactivity. The RKO single cell DNA analysis showed wild type KRAS in 5 
out of 5 cells, and mutated PIK3CA in 5 out of 5 cells. The latter mutation (c.3140 A > G) induces activity of the 
PI3K pathway in the RKO cells, and also in the LS174T cells, as indicated by an inactive FOXO transcription 
factor, even though we found FOXO family members are expressed.
Discussion
Two other approaches have been published for analysing both the genome and transcriptome from the same 
single cell, namely DR-seq13 and G&T-seq14 recently. These are bench protocols which can be automated by using 
a robotic workstation14. By contrast, the approach we have presented here is an integrated approach, in which the 
two crucial process steps, RNA and DNA separation and single cell DNA amplification, have been performed in a 
microfluidic chip. A physical method of RNA and DNA separation is implemented using a microfluidic chip and 
a two-stage lysis protocol. Compared to the DR-seq approach, the use of a physical method to separate the gDNA 
from the RNA has three advantages. First, there is no need for masking-out the coding sequences when mapping 
the gDNA fraction to the genome13, implying that mutations in genes which are not expressed or are suppressed 
can also be found. Secondly, the whole cytosol and nuclear extract is used, while in the DR-seq approach the 
sample is split in half13. Thirdly, conventional, commercial kits for single cell RNA and DNA amplification can be 
used, as the two nucleic acids fractions are separated, whereas DR-seq requires an additional in-vitro transcription 
step in the RNA sample preparation13. The G&T-seq method does use physical means for separating the RNA and 
Figure 4. Lorenz and coverage graphs. (a) Lorenz graph and (b) coverage graph of the DNA sequencing 
coverage for the single cells samples LS174T (green lines) and a bulk LS174T sample (black) shown as reference.
www.nature.com/scientificreports/
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DNA by using oligo-dT coated magnetic beads to extract the mRNA. Here the advantage of our approach is that 
the processing is done within a microfluidic chip, which limits handling, transfer and separation steps and thereby 
reduces sample loss and contamination. This is particularly important, when processing the DNA and RNA con-
tent from a single cell13. Note that the G&T-seq protocol involves a number of handling steps to separate the RNA 
and DNA. To maximize gDNA recovery, the beads capturing the RNA have to be washed four times and the eluate 
of each wash has to be added to the original supernatant with the gDNA. Finally, a microfluidic cartridge in which 
processing is done may also bring cost benefits through reduction of labor and use of standard commercial kits, 
which should outweigh the costs of the dedicated instrument required.
The RNA-seq data have been analyzed based on a Bayesian model for the canonical Wnt pathway, known 
to be active in colorectal cancer (cell lines)16. Similar Bayesian models are being developed for the other tumor 
driving pathways. Once these additional models become available, one could determine which tumor driving 
pathways are active from the measured gene expression profiles, without prior knowledge which pathway may be 
active. Since tumors tend to be heterogeneous and comprised of (sub)clones, this work would enable a systematic 
approach to find these clones, by first establishing which tumor driving pathways are active and then finding the 
mutations that drive them, using single cell resolution. This approach can be seen as an example of an integrative 
network modelling approach (see refs 22 and 23). Being able to see which tumor driving signalling pathways are 
active as the disease progresses, may provide new insights into tumor evolution, and may enable the selection of 
targeted drug combinations to treat cancer patients more effectively.
Conclusion
We have presented a method using a microfluidic chip and a two-stage lysis protocol, to extract both the RNA and 
the DNA from the same single cell. An important advantage of this approach is that the DNA and RNA content 
from a single cell can be processed directly after lysis, owing to the picoliter cell trap volume, without the need 
for additional washing and handling steps that increase the risk of removing some of the nucleic acid content. 
Moreover, in contrast to the G&T method, our method will also extract RNAs without a poly-A tail24, and thus 
could enable the partitioning of any RNAs between cytosol and nucleus25, 26.
Sequencing of each fraction enables determination of pathway activity from the cytosol faction and the muta-
tions responsible for driving this pathway from the nuclear fraction. This ability to predict pathway activity indi-
cates that the Bayesian pathway-modelling approach, previously only applied to bulk samples, can be extended 
to single cells. Identifying active pathways and their driver mutations and weighing their contribution by single 
cell analysis of a heterogeneous tumour could be important for guiding targeted therapy. Pathway analysis by dif-
ferential on-chip DNA and RNA extraction could also be a very promising approach for analysis of individually 
captured circulating tumour cells.
Methods
System. The set-up used to monitor and control single cells in the microfluidic chip and enabling movement, 
trapping, RNA/DNA extraction and amplification comprises the following modules:
•	 A microscopy module enabling epi-fluorescence and bright-field imaging
•	 A temperature module
•	 A flow control module
•	 Microfluidic chip adaptor and tube connector
•	 XY translation and focus adjustment unit
Each module is operated through a common graphical user interface program (GUI) and characterized as 
follows (see Fig. 1):
a) Microscopy module: The main elements of the module are the following components: Microscope objec-
tive (Wild Heerbrugg: 10X, NA 0.45). Excitation light source for fluorescence microscopy: A LED with center 
wavelength at 470 nm (Thorlabs model M470L3) equipped with collimator lenses. Fluorescence filters (Semrock, 
barrier filter model 733–527/645–25, dichroic mirror model 733–474/23–25, excitation filter model 733–
495/605-Di01-25 × 36). CMOS imaging sensor (Fairchild, CIS1910) with 1920 × 1080 pixels, and pixel size 6.5 μ 
m, using a home-built image board. The bright-Field illuminator delivers light from a LED with center wave-
length of 505 nm.
b) XY translation and focus adjustment unit: The XY translation is managed by moving the microfluidic chip 
in the Y-direction and illuminator-objective arm in the X-direction. The z-translation for focussing is performed 
by moving the objective along the optical axis.
c) Flow control module: The control of moving and trapping the cells in the microfluidic chip is achieved by 
applying minor elevated air pressure of typically 5–10 mbar onto the inlet channels. The pressure is delivered by 
an external pressure-based flow control module (Fluigent, MFCSTM–EZ 4C). This provides 4 pneumatic, inde-
pendently controllable channels that are connected to the tube connector of the chip adaptor, see Fig. 1a and b.
d) Temperature module: The heating and cooling of the microfluidic chip is done by three Peltier elements. 
The temperature profile used for the nucleic acid amplification within the chip is regulated by PID control of the 
Peltier elements. Temperature feedback is provided by a thermo-couple situated inside the heating /cooling plate 
that the microfluidic chip is clamped on (see Fig. 1). Due to a temperature difference between this plate and the 
sample volume, the plate temperature is elevated by a calibrated offset.
Device fabrication. 30 μm deep microchannels were created by reactive ion etching in silicon and replicated in 
nickel by electroplating. The nickel master was replicated in TOPAS 5013 (Topas, Germany) by injection molding 
www.nature.com/scientificreports/
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using a tool creating twelve holes for fluidic connections. The device was sealed by UV-assisted thermal bonding 
of a 150 μm thick TOPAS 5013 foil (Topas, Germany).
Cell culture. The colorectal cancer cell line samples came from the Weatherall Institute of Molecular Medicine 
(Oxford, U.K.), which maintains a large collection of colorectal cancer cell lines. The cell lines CC20, LS174T, 
LS180, and SW1222, were cultured in DMEM (Gibco, Life Technologies). RKO was cultured in RPMI (Gibco, 
Life Technologies) all media were supplemented with 10% FBS (Gibco, Life Technologies), 2 mM Glutamax (Life 
Technologies) and 1% pen/strep (Gibco, Life Technologies). Cells were grown at 37 °C in a humidified incu-
bator containing 10% CO2. Prior and after experiments, the cells were tested for Mycoplasma contamination 
(Agilent). For verification purposes an additional LS174T cell line sample was purchased directly from the ATCC 
(Manassas, VA, USA).
Cell staining. Freshly prepared cells were detached with 0.25% trypsin containing 0.04% EDTA (Gibco). Upon 
detachment the cells were taken up in medium and spun down, the cells were washed once with PBS and finally 
resuspended in PBS containing 1 μM calcein-AM (Sigma Aldrich). Cells were incubated for 30 minutes at room 
temperature prior to loading them onto the chip. The on-chip nuclear staining was achieved during lysis of the 
cellular membrane by applying a lysis buffer consisting of 0.5x TBE (Sigma Aldrich) containing 0.5 % Triton-X100 
(Sigma Aldrich) and 1 μM YOYO-1 (ThermoFischer Scientific). (See main text and Fig. 2).
RNA extraction. RNA was extracted and purified from the cell line samples described in the cell culture section 
using a commercial kit (VERSANT Sample Preparation 1.0 Reagents kit) according to manufacturer’s instruc-
tions. The cells were trypsinized, washed once with PBS and resuspended in PBS. RNA was extracted from ≈105 
cells and stored at −80 °C.
Sample preparation. The RNA fraction of a single cell was converted to cDNA and amplified using the 
SMART-Seq v4 Ultra Low Input RNA Kit for Sequencing (Takara/ Clontech) according to manufacturer’s instruc-
tions27. For the calibration and verification of the pathway model also higher inputs of cells or purified RNA were 
used for cDNA synthesis and amplification using the same kit. The gDNA fraction of a single cell was amplified 
on chip using the REPLI-g Single Cell kit (Qiagen).
Sequencing. Sequencing libraries were prepared using the Nextera libray preparation kit from inputs as low as 
10 ng. The Nextera XT DNA library preparation kit was used when the input was only ≥1 ng of cDNA or DNA. 
After cluster formation on the Illumina cBot using the HiSeq Paired End Cluster Kit v4, sequencing was done on 
the Illumina HiSeq. 2500, using 2 × 125 bp paired-end sequencing with the HiSeq SBS kit v4 (250 cycles).
Bioinformatic analysis. The DNA sequencing reads were aligned to the reference human genome GRCh37 
release 60 using the Burrows-Wheeler alignment tool version 0.7.5a28. Reference coverage statics were computed 
with the BEDtool version 2.9.0 on the bam files.
For alignment of the RNA sequencing data the pipeline proposed by Fonseca et al.29 was used (version 0.4.2, 
mapper = tophat2 (v2.0.10), quantification method = htseq. 2 (v0.6.1p1)). Determination of the gene expression 
levels was described in reads per kbase per million mapped reads, RPKM.
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